AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01735539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 x 3.75g Mixed EAA Pulses
Description: Oral; in aqueous solution
Study NCT00678379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)
Study NCT01361607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Study NCT03661749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean catch
Description: clean catch technique applied to collect urine for PR/CR ratio
Study NCT01361607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (GA-0034)
Study NCT01611168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Algorithms
Description: subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
Study NCT04013022 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise History
Description: The groups will be divided based on their exercise history
Study NCT05680207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes self- management education (DSME) program
Description: We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
Study NCT00575328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Description: 3g/day of Maca Root for 12 weeks.
Study NCT00575328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study NCT00179452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT04051632 — intervention group
Intervention type: DEVICE
Intervention: Medtronic 670G insulin pump
Description: * percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range
Study NCT00404586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW784568X
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
Study NCT00404586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
Study NCT00404586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
Study NCT00404586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to GW784568X as aqueous nasal spray.
Study NCT00068237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salivary gland transfer
Description: Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
Study NCT00068237 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy
Description: Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
Study NCT01004120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bimuno
Description: 5.5g daily intake
Study NCT01004120 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 5.5g daily intake
Study NCT01735539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g EAA Bolus supplemented with 3g Arginine
Description: Oral; in aqueous solution
Study NCT02995603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-X patient rotation
Description: Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
Study NCT00033254 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo conventional radiation therapy
Study NCT00033254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo conventional radiation therapy
Study NCT00033254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00033254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00033254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03114254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.
Study NCT01793064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention (AI)
Description: Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
Study NCT01793064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Intervention (SI)
Description: Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website.
Study NCT00201006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Description: Biweekly group behavioral counseling sessions conducted in a face-to-face format
Study NCT00201006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Biweekly telephone counseling sessions conducted in a one-on-one format
Study NCT00201006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mail contact
Description: Biweekly written newsletters with weight management advice delivered via U.S. mail
Study NCT03869775 — intervention group
Intervention type: DEVICE
Intervention: perfusion index monitor
Description: perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
Study NCT03869775 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ewing test
Description: ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
Study NCT02523313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Placebo
Description: Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
Study NCT02523313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Study NCT02523313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo Control
Description: Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Study NCT03348891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tumor biopsy specimens and blood samples
Description: Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
Study NCT00919243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 1 mg/kg/day with a maximum dose of 60 mg/day given orally
Study NCT00919243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
Study NCT03239379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: Injectable peptide antagonist of IL-2, IL-9 and IL-15
Study NCT03239379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT02126293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Study NCT02126293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat blood and urine tests
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: capsule
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: over-encapsulated to match MBX-102 and placebo
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day
Study NCT01629251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Description: Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
Study NCT01629251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin delivery
Description: Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
Study NCT01351649 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: middle school physical activity intervention for girls
Description: Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model.
Study NCT01351649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: middle school physical activity intervention for girls
Description: Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model.
Study NCT01786161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin continuous infusion
Description: Vancomycin 24 hour intravenous continuous infusion
Study NCT00814372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day
Study NCT01737112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study NCT01750268 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management Counseling
Description: Brief alcohol and medication counseling
Study NCT01750268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management Counseling
Description: Brief alcohol and medication counseling
Study NCT01750268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Experimental medication
Study NCT01750268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00966940 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004% ophthalmic solution (TRAVATAN)
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study NCT00494286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abused-focused cognitive behavioral therapy (AF-CBT)
Description: Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
Study NCT00494286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
Study NCT00128908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Continuous Highly Active Antiretroviral Therapy (HAART)
Study NCT00128908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapidly Cycled HAART
Study NCT02459132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval exercise
Description: See arm/group description
Study NCT00788632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient educational DVD and brochure
Description: Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster.
Study NCT00788632 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician web modules
Description: Web based osteoporosis continuing medical education (CME) materials
Study NCT00788632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System
Description: Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
Study NCT03287375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Study NCT04513535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Manipulation
Description: A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
Study NCT04513535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Manipulation
Description: Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
Study NCT04513535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glenohumeral posterior glide mobilization
Description: Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
Study NCT04513535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleeper stretch
Description: Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
Study NCT01786161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin intermittent dosing interval
Description: Vancomycin intravenous infusion at rate 1000mg/hr
Study NCT02705365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
Study NCT02559479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with a low-calorie 18%-protein diet
Study NCT00966940 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tafluprost 0.0015% ophthalmic solution
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study NCT02559479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss interventional study with a low-calorie 35%-protein diet
Study NCT00611091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: Follow-up appointment needs/plans
Study NCT00611091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: Laboratory follow-up needs
Study NCT00611091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic delivery of enhanced discharge information to the ambulatory physician
Description: New medications
Study NCT04208815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk Polar Lipids
Description: Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
Study NCT02577289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
Description: • The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)